<DOC>
	<DOC>NCT02208284</DOC>
	<brief_summary>PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of PF-06427878 in healthy adult subjects.</brief_summary>
	<brief_title>A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects of non childbearing potential. Body Mass Index (BMI) of 17.5 to 35.4 kg/m2; and a total body weight &gt;50 kg Subjects with fasting TG level of &gt;=90 mg/dL and &lt;=500 mg/dL following an overnight fast Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Single Ascending Dose</keyword>
	<keyword>healthy subjects</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Lipid Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>